{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:24:39Z","timestamp":1784370279126,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In 2019, the World Health Organization (WHO) changed its recommendations for pregnant women living with HIV from efavirenz-based to dolutegravir-based therapy due to its superior efficacy, tolerability and resistance profile. Perinatal exposure to antiretrovirals may influence infant growth, but limited data exist on the effects of specific regimens over time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim:<\/jats:title>\n            <jats:p>This study aimed to compare growth trajectories over the first 72 weeks of life among infants exposed to dolutegravir-based versus efavirenz-based therapy during late pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The DolPHIN-2 trial was a randomized, open-label trial conducted in South Africa and Uganda, researching the efficacy of dolutegravir-based versus efavirenz-based therapy in pregnant women living with HIV, initiating treatment in the third trimester. In this secondary analysis, we compared growth trajectories until 72 weeks postpartum between HIV-exposed uninfected infants perinatally exposed to dolutegravir-based versus efavirenz-based therapy. Measures of infant weight, length and head circumference were converted to WHO-defined weight-for-age, weight-for-length, length-for-age and head circumference-for-age Z-scores. Subsequently, Z-scores were compared across treatment arms, using linear mixed-effect models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After exclusions, 232 infants remained (dolutegravir: n = 116; efavirenz: n = 116). In both crude models and models adjusted for study site and maternal height, length-for-age Z-scores were 0.277 units higher in the dolutegravir arm. No statistically significant impact of treatment was observed for other outcomes. In both study arms, a decline in mean length-for-age Z-scores occurred over the first 72 weeks, while mean weight-for-age Z-scores declined between weeks 48 and 72.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our data support the WHO in recommending dolutegravir-based therapy over efavirenz-based therapy in pregnant women living with HIV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004902","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T20:01:47Z","timestamp":1752782507000},"page":"1066-1071","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Effects on the Growth of HIV-exposed Uninfected Infants of Initiating Dolutegravir-based Versus Efavirenz-based cART in Late Pregnancy (DolPHIN-2)"],"prefix":"10.1097","volume":"44","author":[{"given":"Lisa","family":"Hagens","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3699-2993","authenticated-orcid":false,"given":"Lisanne A. H.","family":"Bevers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thokozile R.","family":"Malaba","sequence":"additional","affiliation":[{"name":"Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia Cornelia","family":"Nassiwa","sequence":"additional","affiliation":[{"name":"Research Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mrubata","sequence":"additional","affiliation":[{"name":"Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Theunissen","sequence":"additional","affiliation":[{"name":"Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengjie","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Read","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[{"name":"Research Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Myer","sequence":"additional","affiliation":[{"name":"Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Waitt","sequence":"additional","affiliation":[{"name":"Research Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"R2-20251013","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S1473-3099(16)00055-4","article-title":"HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination.","volume":"16","author":"Evans","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R4-20251013","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","article-title":"Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.","volume":"7","author":"Kintu","year":"2020","journal-title":"Lancet HIV"},{"key":"R5-20251013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAD.0000000000000895","article-title":"In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana.","volume":"30","author":"Powis","year":"2016","journal-title":"AIDS"},{"key":"R6-20251013","doi-asserted-by":"crossref","first-page":"ofx187","DOI":"10.1093\/ofid\/ofx187","article-title":"In Utero ART exposure and birth and early growth outcomes among HIV-exposed uninfected infants attending immunization services: results from National PMTCT Surveillance, South Africa.","volume":"4","author":"Ramokolo","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R7-20251013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12887-017-0828-6","article-title":"Growth of HIV-exposed uninfected, compared with HIV-unexposed, Zambian children: a longitudinal analysis from infancy to school age.","volume":"17","author":"Rosala-Hallas","year":"2017","journal-title":"BMC Pediatr"},{"key":"R8-20251013","doi-asserted-by":"crossref","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","article-title":"Comparative safety of antiretroviral treatment regimens in pregnancy.","volume":"171","author":"Zash","year":"2017","journal-title":"JAMA Pediatr"},{"key":"R9-20251013","doi-asserted-by":"crossref","first-page":"ofab308","DOI":"10.1093\/ofid\/ofab308","article-title":"Integrase strand transfer inhibitors and weight gain in children and youth with perinatal human immunodeficiency virus in the DC Cohort.","volume":"8","author":"Koay","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R11-20251013","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1542\/peds.2014-3111","article-title":"Linear growth and child development in low- and middle-income countries: a meta-analysis.","volume":"135","author":"Sudfeld","year":"2015","journal-title":"Pediatrics"},{"key":"R12-20251013","doi-asserted-by":"crossref","first-page":"e0191903","DOI":"10.1371\/journal.pone.0191903","article-title":"Determinants of late antenatal care presentation in rural and peri-urban communities in South Africa: a cross-sectional study.","volume":"13","author":"Ebonwu","year":"2018","journal-title":"PLoS One"},{"key":"R13-20251013","doi-asserted-by":"crossref","first-page":"e16204","DOI":"10.2196\/16204","article-title":"PediTools electronic growth chart calculators: applications in clinical care, research, and quality improvement.","volume":"22","author":"Chou","year":"2020","journal-title":"J Med Internet Res"},{"key":"R15-20251013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bpobgyn.2018.02.004","article-title":"Fetal growth restriction in twins.","volume":"49","author":"Townsend","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R16-20251013","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/INF.0000000000001574","article-title":"Child growth according to maternal and child HIV status in Zimbabwe.","volume":"36","author":"Omoni","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20251013","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jpeds.2013.02.002","article-title":"Maternal height and child growth patterns.","volume":"163","author":"Addo","year":"2013","journal-title":"J Pediatr"},{"key":"R18-20251013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12889-021-12476-z","article-title":"Growth patterns of infants with in-utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia.","volume":"22","author":"Nyemba","year":"2022","journal-title":"BMC Public Health"},{"key":"R19-20251013","doi-asserted-by":"crossref","first-page":"e0224295","DOI":"10.1371\/journal.pone.0224295","article-title":"Growth of young HIV-infected and HIV-exposed children in western Kenya: a retrospective chart review.","volume":"14","author":"McHenry","year":"2019","journal-title":"PLoS One"},{"key":"R20-20251013","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/ciaa076","article-title":"Mortality, human immunodeficiency virus (HIV) transmission, and growth in children exposed to HIV in Rural Zimbabwe.","volume":"72","author":"Evans","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R21-20251013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11904-019-00459-0","article-title":"Growth and neurodevelopment of HIV-exposed uninfected children: a conceptual framework.","volume":"16","author":"Wedderburn","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R22-20251013","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.pmed.1002895","article-title":"Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study).","volume":"16","author":"Waitt","year":"2019","journal-title":"PLoS Med"},{"key":"R23-20251013","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0b013e31823ff052","article-title":"Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.","volume":"59","author":"Cressey","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-20251013","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/QAI.0b013e31817bbc21","article-title":"Efavirenz in human breast milk, mothers\u2019, and newborns\u2019 plasma.","volume":"48","author":"Schneider","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-20251013","doi-asserted-by":"crossref","first-page":"e2020008029","DOI":"10.1542\/peds.2020-008029","article-title":"Breastfeeding, physical growth, and cognitive development.","volume":"147","author":"Wallenborn","year":"2021","journal-title":"Pediatrics"},{"key":"R26-20251013","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/INF.0000000000002678","article-title":"Differences in growth of HIV-exposed uninfected infants in ethiopia according to timing of in-utero antiretroviral therapy exposure.","volume":"39","author":"Ejigu","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R27-20251013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/QAD.0000000000001302","article-title":"Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.","volume":"31","author":"M le Roux","year":"2017","journal-title":"AIDS"},{"key":"R28-20251013","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(13)60937-X","article-title":"Maternal and child undernutrition and overweight in low-income and middle-income countries.","volume":"382","author":"Black","year":"2013","journal-title":"Lancet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:10:09Z","timestamp":1760375409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004902","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}